Sander J W, Trevisol-Bittencourt P C, Hart Y M, Patsalos P N, Shorvon S D
INSEG-Epilepsy Research Group, Institute of Neurology, London, U.K.
Epilepsy Res. 1990 Dec;7(3):226-9. doi: 10.1016/0920-1211(90)90019-r.
We report the effects of the addition of lamotrigine, a novel antiepileptic drug, to the therapy of 125 patients with severe refractory epilepsy. Forty-five patients (36%) reported adverse experiences and in 19 (15%), the drug was withdrawn. The commonest adverse experiences were diplopia, headache, ataxia, drowsiness, skin rash and deterioration in seizure control. Two patients were withdrawn for other reasons. The remaining 104 patients were followed for a mean of 11 months (range 3-27): 26 (25%) of these showed a marked improvement in seizure frequency (a 50% or more reduction when compared with the pre-trial period), but no patient was rendered seizure-free. Tolerance to the effects of the drug was not seen.
我们报告了在125例严重难治性癫痫患者的治疗中添加新型抗癫痫药物拉莫三嗪的效果。45例患者（36%）报告了不良经历，其中19例（15%）停药。最常见的不良经历是复视、头痛、共济失调、嗜睡、皮疹以及癫痫控制情况恶化。另有2例患者因其他原因停药。其余104例患者平均随访11个月（范围3 - 27个月）：其中26例（25%）癫痫发作频率显著改善（与试验前相比降低50%或更多），但无患者实现无癫痫发作。未观察到对该药效果的耐受性。
